1. Introduction
===============

The chemical investigations on soft corals of the genus *Cladiella* and *Klyxum* \[[@B1-marinedrugs-13-02757],[@B2-marinedrugs-13-02757],[@B3-marinedrugs-13-02757],[@B4-marinedrugs-13-02757],[@B5-marinedrugs-13-02757],[@B6-marinedrugs-13-02757],[@B7-marinedrugs-13-02757],[@B8-marinedrugs-13-02757],[@B9-marinedrugs-13-02757],[@B10-marinedrugs-13-02757],[@B11-marinedrugs-13-02757],[@B12-marinedrugs-13-02757],[@B13-marinedrugs-13-02757],[@B14-marinedrugs-13-02757],[@B15-marinedrugs-13-02757],[@B16-marinedrugs-13-02757],[@B17-marinedrugs-13-02757],[@B18-marinedrugs-13-02757],[@B19-marinedrugs-13-02757],[@B20-marinedrugs-13-02757],[@B21-marinedrugs-13-02757],[@B22-marinedrugs-13-02757],[@B23-marinedrugs-13-02757],[@B24-marinedrugs-13-02757],[@B25-marinedrugs-13-02757],[@B26-marinedrugs-13-02757],[@B27-marinedrugs-13-02757],[@B28-marinedrugs-13-02757],[@B29-marinedrugs-13-02757],[@B30-marinedrugs-13-02757],[@B31-marinedrugs-13-02757],[@B32-marinedrugs-13-02757]\] have afforded series of eunicellin-based diterpenoids, of which many have been shown to exhibit attracting biological activities \[[@B8-marinedrugs-13-02757],[@B10-marinedrugs-13-02757],[@B11-marinedrugs-13-02757],[@B12-marinedrugs-13-02757],[@B13-marinedrugs-13-02757],[@B14-marinedrugs-13-02757],[@B15-marinedrugs-13-02757],[@B16-marinedrugs-13-02757],[@B17-marinedrugs-13-02757],[@B18-marinedrugs-13-02757],[@B19-marinedrugs-13-02757],[@B20-marinedrugs-13-02757],[@B21-marinedrugs-13-02757],[@B22-marinedrugs-13-02757],[@B23-marinedrugs-13-02757],[@B24-marinedrugs-13-02757],[@B25-marinedrugs-13-02757],[@B26-marinedrugs-13-02757],[@B27-marinedrugs-13-02757],[@B28-marinedrugs-13-02757],[@B29-marinedrugs-13-02757],[@B30-marinedrugs-13-02757],[@B31-marinedrugs-13-02757],[@B32-marinedrugs-13-02757]\]. We have previously isolated some bioactive eunicellins and steroids from a Taiwanese soft coral *Cladiella hirsuta*. Our recent studies of *C. hirsuta* haveled to the discovery of 18 eunicellin-based diterpenoids, hirsutalins A--R \[[@B29-marinedrugs-13-02757],[@B30-marinedrugs-13-02757],[@B31-marinedrugs-13-02757]\], some of which have been found to possess cytotoxic \[[@B29-marinedrugs-13-02757],[@B31-marinedrugs-13-02757]\] and anti-inflammatory activities \[[@B29-marinedrugs-13-02757],[@B30-marinedrugs-13-02757],[@B31-marinedrugs-13-02757]\]. In this paper, we further report the isolation of four new eunicellin-based compounds, hirsutalins S--V along with a known compound (--)-6α-hydroxy polyanthellin A (**5**) \[[@B32-marinedrugs-13-02757]\] from *C. hirsuta* ([Chart 1](#marinedrugs-13-02757-f004){ref-type="fig"}). The structures of new compounds were determined by extensive spectroscopic analysis. Cytotoxicity of **1**--**5** against a limited panel of cancer cell lines and their anti-inflammatory activity, determined by their ability to inhibit the generation of super oxide anion and elastase release in *N*-formyl-methionyl-leucyl-phenylalanine/cytochalasin B (fMLP/CB)-induced human neutrophils, were studied in order to discover bioactive compounds from marine environment.
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###### 

Structures of metabolites **1**--**5**.
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2. Results and Discussion
=========================

Hirsutalin S (**1**) was isolated as a colorless oil. The HRESIMS (*m*/*z* 485.2512) of **1** established a molecular formula of C~26~H~38~O~7~. The IR spectrum of **1** showed the presence of hydroxy and carbonyl groups from absorptions at 3463 and 1740 cm^−1^, respectively. The ^1^H and ^13^C NMR data of **1** ([Table 1](#marinedrugs-13-02757-t001){ref-type="table"}) were found to be closely resembled to those of known metabolite hirsutalin R \[[@B32-marinedrugs-13-02757]\]. The only difference was the presence of 2-acetoxybutanoate (δ~C~ 169.0 (C), 73.9 (CH), 24.5 (CH~2~), and 9.7 (CH~3~); 171.0 (C) and 20.6 (CH~3~)) in **1**, instead of 2-butyryloxy butanoate at C-3 of hirsutalin R \[[@B32-marinedrugs-13-02757]\]. This was supported by the HMBC interaction of H-2′′ (δ 2.16) with carbonyl carbon resonating at δ 171.0. Moreover, the ^13^C NMR spectroscopic data ([Table 1](#marinedrugs-13-02757-t001){ref-type="table"}) of **1** showed the presence of two 1,1-disubstituted carbon-carbon double bonds (δ~C~ 147.6 (C) and 118.3 (CH~2~); 145.2 (C) and 111.6 (CH~2~)). The molecular framework of **1** was established by the complete analysis of its COSY and HMBC correlations ([Figure 1](#marinedrugs-13-02757-f001){ref-type="fig"}). In the NOESY spectrum of **1**, the correlations between H-10 with H-1; H-1 with H~3~-19, suggested that H-1, H-10 and H~3~-19 are β-oriented. Besides, correlations of H-2 with H~3~-15 and H-14; H-9 with H-14, suggested that H-2, H-9, H-14 and H~3~-15 are α-oriented. Furthermore, the asymmetric center at C-18 was suggested to be *R*-configured on the basis of NOE correlations between the β-oriented H-1 and H~3~-19 and between the α-oriented H-2 and H-18. As the absolute configuration of hirsutalin A \[[@B29-marinedrugs-13-02757]\] and that of hirsutalin J except C-2′ configuration \[[@B30-marinedrugs-13-02757]\] have been completely assigned based on Mosher's method, thus, the absolute configuration of **1**, except that of C-2′, should be revealed as depicted.
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###### 

NMR spectroscopic data for hirsutalins S (**1**) and T (**2**).

             1              2                                                     
  ---------- -------------- ------------------------------- --------------------- -------------------------------
  1          45.1, CH ^b^   2.24, m                         39.8; 39.7,^f^ CH     2.69, m
  2          90.7, CH       3.70, s                         87.64; 87.61, CH      3.86, d (6.0)
  3          86.0, C                                        74.3, C               
  4          32.4, CH~2~    2.13, m;                        74.2, CH              5.08, dd (8.5, 3.5)
  5          37.2, CH~2~    2.84, t (10.4); 2.35, m         37.9; 37.8, CH~2~     2.90, dq (15.5, 5.0); 1.78, m
  6          206.5, C                                       72.6, CH              4.23, br s
  7          147.6, C                                       147.7, C              
  8          37.2, CH~2~    3.22, dd (13.2, 5.2); 2.40, m   40.1, CH~2~           2.42, m; 2.34, m
  9          78.3, CH       4.07, m                         81.80; 81.76, CH      4.15, m
  10         48.7, CH       3.07, dd (9.6, 7.6)             44.5, CH              2.69, m
  11         145.2, C                                       132.1; 132.0, C       
  12         31.1, CH~2~    2.30, m; 2.11, m                122.02; 121.97, CH    5.46, s
  13         25.8, CH~2~    1.68, m; 1.13, m                22.8; 22.8, CH~2~     2.09, m; 1.91, m
  14         37.3, CH       1.68, m                         34.4; 34.3, CH        1.84, m
  15         22.7, CH~3~    1.48, s                         22.6, CH~3~           1.38, s
  16         118.3, CH~2~   5.62, s; 5.27, s                115.9; 115.8, CH~2~   5.62, s; 5.24, s
  17         111.6, CH~2~   4.85, s; 4.72, s                22.3; 22.2, CH~3~     1.70, s
  18         36.4, CH       1.79, m                         33.8; 33.7, CH        1.84, m
  19         16.3, CH~3~    1.03, d (7.2)                   14.5; 14.3, CH~3~     0.86, d (6.5)
  20         66.4, CH~2~    3.52, d (7.2)                   67.8; 67.6, CH~2~     4.11, dd (9.5, 4.0); 3.89, m
  1′         169.0, C                                       171.4;171.2, C        
  2′         73.9, CH       4.76, t (6.8)                   74.1, CH              4.84, dd (13.0, 6.0)
  3′         24.5, CH~2~    1.87, m                         24.4; 24.3, CH~2~     1.90, m
  4′         9.7, CH~3~     1.03, t (7.6)                   9.4; 9.3, CH~3~       1.03, t (7.5)
  1′′        171.0, C                                       171.1; 171.0, C       
  2′′        20.6, CH~3~    2.16, s                         20.9; 20.5, CH~3~     2.13, s; 2.02, s
  20-OCOPr                                                  173.9; 173.7, C       
                                                            36.2; 35.7, CH~2~     2.27, m;
                                                            18.5; 18.3, CH~2~     1.64, m;
                                                            13.7; 13.6, CH~3~     0.96, t (7.5); 0.94, t (7.5)

^a^ Spectra recorded at 100 MHz in CDCl~3~; ^b^ Attached protons were deduced by DEPT experiments; ^c^ Spectra recorded at 400 MHz in CDCl~3~; ^d^ Spectra recorded at 125 MHz in CDCl~3~; ^e^ Spectra recorded at 500 MHz in CDCl~3~; ^f^ Paired signals due to C-2′ epimeric mixture.

![COSY and HMBC correlations for **1**--**4**.](marinedrugs-13-02757-g001){#marinedrugs-13-02757-f001}

Hirsutalin T (**2**) was also afforded as a colorless oil. Its molecular formula C~30~H~46~O~9~, was determined by HRESIMS (*m*/*z* 573.3036). The ^13^C NMR spectrum ([Table 1](#marinedrugs-13-02757-t001){ref-type="table"}) showed the presence of the 2-acetoxybutanoate (δ~C~ 171.2 (C), 74.1 (CH), 24.3 (CH~2~), and 9.3 (CH~3~); 171.0 (C) and 20.5 (CH~3~)) \[[@B29-marinedrugs-13-02757]\] and an *n*-butyrate (δ~C~173.9 (C), 36.2 (CH~2~), 18.5 (CH~2~), and 13.7 (CH~3~)). Comparison of the NMR data of **2** with those of the known compound hirsutalin A \[[@B29-marinedrugs-13-02757]\], it was found that a 2-hydroxybutyrate at C-3 and a methylene proton at C-4 in hirsutalin A were replaced by a hydroxy group and 2-acetoxybutanoate in **2**, respectively. This was confirmed by the downfield shift of C-3 (δ~C~ 86.9) of hirsutalin A, relative to that of **2** (δ~C~ 74.3), and the HMBC connectivity from H-4 (δ 5.08) to the carbonyl carbon resonating at δ171.2 (C) ([Table 1](#marinedrugs-13-02757-t001){ref-type="table"}). The structure of **2** was unambiguously determined by the extensive analysis of ^1^H--^1^H COSY and HMBC ([Figure 1](#marinedrugs-13-02757-f001){ref-type="fig"}), and NOESY correlations ([Figure 2](#marinedrugs-13-02757-f002){ref-type="fig"}). Moreover, compound **2** was obtained as a C-2′ epimeric mixture with a ratio of about 1:1 reflected by a pair of signals in the ^13^C NMR spectrum. Experiments were tried to separate an individual epimer but they were all unsuccessful.

The new eunicellin, hirsutalin U (**3**), gave the molecular formula C~28~H~44~O~8~S, on the basis of HRESIMS data (*m*/*z* 563.2657). NMR spectroscopic data of **3** ([Table 2](#marinedrugs-13-02757-t002){ref-type="table"}) showed the presence of the 3-methylsulfoxylpropionate substituent (δ~C~ 171.8 (C), 48.92 (CH~2~), 27.1 (CH~2~), and 38.6 (CH~3~)) \[[@B13-marinedrugs-13-02757]\] and an *n*-butyrate (δ~C~ 175.4 (C), 36.5 (CH~2~), 18.5 (CH~2~), and 13.7 (CH~3~)). The spectroscopic data (IR, ^1^H NMR, and ^13^C NMR) of **3** have similar structural features as those of a known one, hirsutalin J \[[@B30-marinedrugs-13-02757]\], except for the 2-butyryloxybutanoate at C-4 and the hydroxy group at C-20 in hirsutalin J were replaced by a *n*-butyrate group and 3-methylsulfoxylpropionate substituent in **3**, respectively. A paired methyl singlets at δ 2.58/2.59 in an approximate 1:1 ratio in the ^1^H NMR spectrum, and the doubling of signals of above methyl group with nearly the equal intensities in ^13^C NMR spectrum were observed, suggested the occurrence of nearly equal quantities of *R* and *S*-configured sulfoxide moiety ([Table 2](#marinedrugs-13-02757-t002){ref-type="table"}). Thus, compound **3** is possibly to be an artifact arisen from the oxidation of its sulfide precursor. The analysis of NOE correlations of **3** revealed the same relative configuration at C-1, C-2, C-3, C-4 C-6, C-9, C-10, C-14 and C-18 as that of **2**. The similar ^1^H NMR, COSY, HMBC correlations ([Figure 1](#marinedrugs-13-02757-f001){ref-type="fig"}) and the analysis of NOE correlations of **3** further revealed the same relative configuration of both compounds. Thus, the structure of **3** was established.
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###### 

NMR spectroscopic data for hirsutalins U and V (**3** and **4**).

                               3                      4                                 
  ---------------------------- ---------------------- ------------------ -------------- -------------------------------
  1                            39.8, CH ^b^           2.66, m            45.2, CH       2.12, m
  2                            87.3, CH               3.85, s            91.8, CH       3.61, s
  3                            74.3, C                                   87.9, C        
  4                            73.4, CH               4.93, m;           36.6, CH~2~    2.64, dd (14.8, 8.4); 1.86, m
  5                            37.7, CH~2~            3.01, m; 1.77, m   29.9, CH~2~    1.66, m; 1.56, m
  6                            72.7, CH               4.17, m            80.6, CH       4.58, d (6.8)
  7                            148.1, C                                  77.0, C        
  8                            40.0, CH~2~            2.35, m            45.5, CH~2~    2.02, m; 1.84, m
  9                            81.3, CH               4.19, m            78.4, CH       4.17, m
  10                           44.5, CH               2.66, m            53.8, CH       3.02, t (7.2)
  11                           132.3, C                                  147.1 , C      
  12                           121.4, CH              5.46, s            31.3 CH~2~     2.28, br d (13.2); 2.08, m
  13                           22.8, CH~2~            2.09, m; 1.91, m   25.3, CH~2~    1.64, m; 1.09, m
  14                           33.6, CH               1.84, m            38.4, CH       1.58, m
  15                           27.7, CH~3~            1.42, s            23.0, CH~3~    1.38, s
  16                           115.3, CH~2~           5.61, s; 5.22, s   22.4, CH~2~    1.25, s
  17                           22.1, CH~3~            1.68, s            109.8, CH~2~   4.71, s; 4.68, s
  18                           34.0, CH               1.82, m            37.5, CH       1.75, m
  19                           15.4, CH~3~            0.90, d (7.2)      10.6, CH~3~    0.80, d (6.8)
  20                           68.5, CH~2~            4.16, m; 4.05, m   66.5, CH~2~    3.53, d (6.8)
  1′                           175.4, C                                  169.1, C       
  2′                           36.5, CH~2~            2.41, m            74.0, CH       4.77, t (6.4)
  3′                           18.5, CH~2~            1.46, m            24.7, CH~2~    1.88, m
  4′                           13.7, CH~3~            0.97, t (7.2)      9.9, CH~3~     1.06, t (7.2)
  1′′                                                                    173.5, C       
  2′′                                                                    35.7, CH~2~    2.38, t (7.2)
  3′′                                                                    18.3, CH~2~    1.69, m
  4′′                                                                    13.6, CH~3~    0.97, t (7.2)
  3-methylsulfoxylpropionate                                                            
  1′′                          171.8; 171.3, C*^d^*                                     
  2′′                          48.92; 48.89, CH~2~    3.04, m; 2.88, m                  
  3′′                          27.1; 26.7, CH~2~      2.83, m; 2.78, m                  
  4′′                          38.6; 38.5, CH~3~      2.59, s; 2.58, s                  

^a^ Spectra recorded at 100 MHz in CDCl~3~; ^b^ Attached protons deduced by DEPT experiments; ^c^ Spectra recorded at 400 MHz in CDCl~3~; ^d^ Paired signals of *R*/*S* stereoisomers at chiral sulfoxide.

Hirsutalin V (**4**) was obtained as a colorless oil with a molecular formula of C~28~H~46~O~8~. IR absorptions of **4** showed the presence of hydroxy and carbonyl groups at 3395 and 1738 cm^−1^, respectively. Two ester carbonyl carbons (δ~C~ 169.1 and 173.5) were correlated with the methine proton (H-2′, δ~H~ 4.77, t, *J* = 6.4 Hz) of a 2-butyryloxybutanoate unit in the HMBC spectrum. By comparison of the NMR data of **4** with those of hirsutalin C \[[@B29-marinedrugs-13-02757]\], it was found that a C-7/C-16 double bond in hirsutalin C was replaced by an oxymethine bearing a methyl and a hydroxy group in **4**, as confirmed by HMBC correlations observed from H~3~-16 (δ 1.25, 3H, s) to C-6 (δ 80.6, CH), C-7 (δ 77.0, C) and C-8 (δ 45.5, CH~2~). The planar structure of **4** was confirmed by careful analysis of COSY, HMBC, and NOESY correlations as shown in [Figure 1](#marinedrugs-13-02757-f001){ref-type="fig"} and [Figure 3](#marinedrugs-13-02757-f003){ref-type="fig"}. Compounds **1**--**4** are likely in the same enantiomeric series as hirsutalin A and hirsutalin J, based on a shared biosynthetic pathway. Thus, these compounds were suggested to possess the absolute configurations as shown in structures **1**--**5**.

Cytotoxicity of compounds **1**--**5** against the proliferation of a limited panel of cancer cell lines, including P388 (murine leukemia), K562 (human erythro myeloblastoid leukemia), A549 (human lung adenocarcinoma), and HT-29 (human colon adenocarcinoma), was evaluated. However, none of the compounds showed any appreciable cytotoxicity at 20 μM. The *in vitro* pro-inflammatory of compounds **1**, **2**, and, **4** were evaluated by suppressing *N*-formyl-methionyl-leucyl-phenyl-alanine/cytochalasin B (fMLP/CB)-induced superoxide anion (O~2~^−•^) generation and elastase release in human neutrophils. As shown in [Table 3](#marinedrugs-13-02757-t003){ref-type="table"}, none of compounds showed significant reduction on the expression of superoxide anion generation, relative to the control cells stimulated with fMLP/CB at a concentration of 10 μg/mL. Further, compound **1** exhibited moderate inhibitory activity against elastase release (46.7% ± 8.0%), though it has shown poor superoxide anion generation (5.8% ± 0.8%) in the same fMLP/CB-stimulated cells at a concentration of 10 μg/mL.

![Key NOESY correlations for **4**.](marinedrugs-13-02757-g003){#marinedrugs-13-02757-f003}
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###### 

Effect of compounds **1**, **2**, and, **4** on superoxide anion generation and elastase release in *N*-formyl-methionyl-leucyl-phenylalanine/cytochalasin B (fMLP/CB)-induced human neutrophils at 10 μg/mL.

  Compounds   Superoxide Anion   Elastase Release
  ----------- ------------------ ------------------
  1           5.8 ± 0.8 \*\*     46.7 ± 8.0 \*\*
  2           6.6 ± 3.4          19.3 ± 5.6 \*
  4           0.9 ± 2.6          4.8 ± 5.6

Percentage of inhibition (Inh %) at 10 μM concentration. Results are presented as mean ± S.E.M. (*n* = 3 or 4). \* *p* \< 0.05, \*\* *p* \< 0.01 compared with the control value.

3. Experimental Section
=======================

3.1. General Experimental Procedures
------------------------------------

Silica gel (230--400 mesh, Merck, Darmstadt, Germany) was used for column chromatography. Precoated silica gel plates (Merck, Kieselgel 60 F-254, 0.2 mm) were used for analytical TLC. High-performance liquid chromatography was performed on a Hitachi L-2455 HPLC apparatus (Hitachi Ltd., Tokyo, Japan) with a Supelco C~18~ column (250 × 21.2 mm, 5 μm). NMR spectra were recorded on a Varian UNITY INOVA-500 FT-NMR a Varian 400MR FT-NMR instrument (Varian Inc., Palo Alto, CA, USA) at 400 MHz for ^1^H and 100 MHz for ^13^C in CDCl~3~. LRMS and HRMS were obtained by ESI on a Bruker APEX II mass spectrometer (Bruker, Bremen, Germany). Optical rotations were measured on a JASCO P-1020 polarimeter. IR spectra were recorded on a JASCO FT/IR-4100 infrared spectrophotometer (Japan Spectroscopic Corporation, Tokyo, Japan).

3.2. Animal Material
--------------------

The animal *Cladiella hirsuta* was collected by hand using SCUBA off the coast of Sianglu Islet (23°32′ N, 119°38′ E) in the region of Penghu Islands, in June 2008, at a depth of 10 m, and was stored in a freezer until extraction. A voucher sample (PI-20080610-17) was deposited at the Department of Marine Biotechnology and Resources, National Sun Yat-sen University.

3.3. Extraction and Separation
------------------------------

The frozen bodies of *C. hirsuta* (3.1 kg, wet wt) were sliced and exhaustively extracted with acetone (3 × 10 L).The organic extract was concentrated to an aqueous suspension and was partitioned between ethyl acetate (EtOAc) and H~2~O. The EtOAc layer was dried with anhydrous Na~2~SO~4~. After removal of solvent in vacuo, the residue (32.8 g) was subjected to column chromatography on silica gel and eluted with EtOAc in *n*-hexane (0%--100% of EtOAc, gradient) and further with MeOH in EtOAc of increasing polarity to yield 25 fractions. Fraction 18, eluting with *n*-hexane--EtOAc (1:1), was rechromatographed over a Sephadex LH-20 column using acetone as the mobile phase to afford four subfractions (A1--A4). Subfractions A3 and A4 were separated by reversed-phase HPLC (MeOH--H~2~O, 3:1 and 2:1) to afford compound **1** (5.8 mg). Fraction 19, eluting with *n*-hexane--EtOAc (1:2), was rechromatographed over a Sephadex LH-20 column, using acetone as the mobile phase, to afford four subfractions (B1--B4). Subfractions B2 and B3 were separated by reversed-phase HPLC (acetonitrile--H~2~O, 3:1 and 2:1) to afford compounds **2** (1.5 mg) and **5** (1.3 mg). Fraction 23, eluting with EtOAc (1:2), was rechromatographed over a Sephadex LH-20 column, using acetone as the mobile phase, to afford four subfractions (B1--B4). Subfractions B2 and B3 were separated by reversed-phase HPLC (acetonitrile--H~2~O, 1.5:1) to afford compounds **3** (2.6 mg) and **4** (1.5 mg).

Hirsutalin S (**1**): colorless oil; \[α\]^25^~D~ +66 (*c* 0.40, CHCl~3~); IR (neat) ν~max~ 3463 and 1740 cm^−1^;^13^C and ^1^H NMR data (400 MHz; CDCl~3~), see [Table 1](#marinedrugs-13-02757-t001){ref-type="table"}; ESIMS *m*/*z* 485 \[M + Na\]^+^; HRESIMS *m*/*z* 485.2512 \[M + Na\]^+^ (calcd for C~26~H~38~O~7~Na, 485.2515) ([Supplementary Information, Figures S1--S3](#marinedrugs-13-02757-s001){ref-type="supplementary-material"}).

Hirsutalin T (**2**): colorless oil; \[α\]^25^~D~ +26.3 (*c* 0.43, CHCl~3~); IR (neat) ν~max~ 3452 and 1738 cm^−1^; ^13^C and ^1^H NMR data (500 MHz; CDCl~3~), see [Table 1](#marinedrugs-13-02757-t001){ref-type="table"}; ESIMS *m*/*z* 573 \[M + Na\]^+^; HRESIMS *m*/*z* 573.3036 \[M + Na\]^+^ (calcd for C~30~H~46~O~9~Na, 573.3039) ([Supplementary Information, Figures S4--S6](#marinedrugs-13-02757-s001){ref-type="supplementary-material"}).

Hirsutalin U (**3**): colorless oil; \[α\]^25^~D~ +11 (*c* 0.74, CHCl~3~); IR (neat) ν~max~ 3442 and 1733 cm^−1^; ^13^C and ^1^H NMR data (400 MHz; CDCl~3~), see [Table 2](#marinedrugs-13-02757-t002){ref-type="table"}; ESIMS *m*/*z* 563 \[M + Na\]^+^; HRESIMS *m*/*z* 563.2657 \[M + Na\]^+^ (calcd for C~28~H~44~O~8~SNa, 563.2654) ([Supplementary Information, Figures S7--S9](#marinedrugs-13-02757-s001){ref-type="supplementary-material"}).

Hirsutalin V (**4**): colorless oil; \[α\]^25^~D~ −18.1 (*c* 0.51, CHCl~3~); IR (neat) ν~max~ 3395 and 1738 cm^−1^; ^13^C and ^1^H NMR data (400 MHz; CDCl~3~), see [Table 2](#marinedrugs-13-02757-t002){ref-type="table"}; ESIMS *m*/*z* 533 \[M + Na\]^+^; HRESIMS *m*/*z* 533.3094 \[M + Na\]^+^ (calcd for C~28~H~46~O~8~Na, 533.3092) ([Supplementary Information, Figures S10--S12](#marinedrugs-13-02757-s001){ref-type="supplementary-material"}).

3.4. Cytotoxicity Testing
-------------------------

Cell lines were purchased from the American Type Culture Collection (ATCC). Cytotoxicity assays of compounds **1**--**5** were performed using the Alamar Blue assay \[[@B33-marinedrugs-13-02757],[@B34-marinedrugs-13-02757]\].

3.5. In Vitro Anti-Inflammatory Assay
-------------------------------------

Human neutrophils were obtained using dextran sedimentation and Ficoll centrifugation. Measurements of superoxide anion generation and elastase release were performed according to previously described procedures. \[[@B35-marinedrugs-13-02757],[@B36-marinedrugs-13-02757]\]. LY294002, a phosphatidylinositol-3-kinase inhibitor, was used as a positive control for inhibition of superoxide anion generation and elastase release with percentage inhibitions of 96.1% ± 4.9% in 10 μg/mL and 97.9% ± 7.7% in 10 μg/mL, respectively.

4. Conclusions
==============

Our investigation demonstrated that the soft coral, *C. hirsuta*, could be a good source of bioactive substances. It is worthwhile to mention that eunicellin-type metabolite containing a sulfoxide, compound **3**, was discovered for the first time from the soft coral *C. hirsuta*. Compound **1** was shown to display inhibitory activity against elastase release.
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Click here for additional data file.
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